2024 Annual Meeting | H217 - Clinical Trials Diversity: A Surmountable Problem (Research Hub)

Date Wednesday 04/17/24

Time 01:00 PM - 01:30 PM MDT Add To Calendar

Location Colorado Convention Center | Exhibit Hall B-E

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Hubs (Research)

Director(s) Richard T. Benson, MD, PhD, FAAN, Yazmin Odia, MD, MS, FAAN, Shibani S. Mukerji, MD, PhD

Topic(s) General Neurology, Education, Research, and Methodology

Learning Objectives The lack of diversity in clinical trials is a problem. Join us to discuss why and how diversity is integral to clinical trial conduct and impact.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Practice-based Learning and Improvement, Systems-based Practice

Program Level Introductory

Program Tracks Diversity, Equity, and Inclusion

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:30 PM MDT	Speaker	Clinical Trials Diversity: A Surmountable Problem Richard T. Benson, MD, PhD, FAAN, Yazmin Odia, MD, MS, FAAN, Shibani S. Mukerji, MD, PhD, Claire Riley, MD, FAAN

Faculty Disclosures
Richard T. Benson, MD, PhD, FAAN	Dr. Benson has received personal compensation in the range of $100,000-$499,999 for serving as a Federal employee with HHS/NIH.
Yazmin Odia, MD, MS, FAAN	Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile.
Shibani S. Mukerji, MD, PhD	Dr. Mukerji has stock in Gilead Science. The institution of Dr. Mukerji has received research support from NIH. The institution of Dr. Mukerji has received research support from Massachusetts General Hospital.
Claire Riley, MD, FAAN	Dr. Riley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viracta. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics.